Shah NP et al. - In a dose- and schedule-optimization study of dasatinib in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia, it was shown that dasatinib retains the efficacy of 70 mg twice daily with less toxicity. Intermittent target inhibition with tyrosine kinase inhibitors may preserve efficacy and reduce adverse events Methods
670 pts with imatinib-resistant or -intolerant CP-CML were randomly assigned 1:1:1:1 between 4 dasatinib treatment groups: 100 mg once daily, 50 mg twice daily, 140 mg once daily, or 70 mg twice daily
Results
With minimum follow-up of 6 months, marked and comparable hematologic and cytogenetic response rates were observed across the 4 groups
Time to and duration of cytogenetic response were similar as was progression-free survival
Compared with the 70-mg twice-daily regimen, dasatinib 100 mg once daily resulted in significantly lower rates of pleural effusion and grade 3 to 4 thrombocytopenia, and fewer pts required dose interruption, reduction, or discontinuation
See all
